De Paoli P, Carbone A
Eur Rev Med Pharmacol Sci. 2016 Apr;20(7):1288-94.
Twenty years after the discovery of Kaposi's Sarcoma Herpes Virus (KSHV), many aspects of the pathogenesis have been discovered and innovative approaches are presently applied to the diagnosis and treatment of KSHV associated diseases. The virus is coupled to different types of cancers, as well as to syndromes combined with increased inflammatory response or with immunoreconstitution in immunocompromised hosts. The etiopathological diagnosis of KSHV associated cancers relies on the demonstration of the virus in tumor samples, as well as in the peripheral blood of infected subjects. Novel treatment strategies related to the pathogenetic events of KSHV associated diseases have been recently studied, that are based on drugs able to induce oncolysis by promoting a viral lytic phase or on the blockade of v-IL6, a cytokine with tumor promoting activities. In addition, antiangiogenetic strategies have also been applied to treat KSHV associated cancers. Despite these important discoveries, some aspects of KSHV associated diseases are presently not completely clear and, consequently, response to treatment strategies is still suboptimal.
在发现卡波西肉瘤疱疹病毒(KSHV)20年后,其发病机制的许多方面已被揭示,目前创新方法也被应用于KSHV相关疾病的诊断和治疗。该病毒与不同类型的癌症相关,也与免疫功能低下宿主中炎症反应增强或免疫重建相关的综合征有关。KSHV相关癌症的病因病理诊断依赖于在肿瘤样本以及受感染个体外周血中检测到该病毒。最近研究了与KSHV相关疾病发病机制相关的新型治疗策略,这些策略基于能够通过促进病毒裂解期诱导肿瘤溶解的药物,或基于阻断具有肿瘤促进活性的细胞因子v-IL6。此外,抗血管生成策略也已应用于治疗KSHV相关癌症。尽管有这些重要发现,但KSHV相关疾病的某些方面目前仍不完全清楚,因此,对治疗策略的反应仍不理想。